The effect of sorafenib on the incidence of chemically induced hepatocellular carcinoma with non-alcoholic fatty liver or steatohepatitis.

• Project/Area Number: 25461808
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: Hamamatsu University School of Medicine
• Principal Investigator: Takehara Yasuo 浜松医科大学, 医学部附属病院, 教授 (70188217)
• Co-Investigator(Kenkyū-buntansha): FUJIE Michio 浜松医科大学, 光尖端医学教育研究センター, 技術補佐員 (90397373)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Project Status: Completed (Fiscal Year 2015)
• Budget Amount: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000); Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000); Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
• Keywords: NASH / NAFLD / HCC / MRI / sorafenib / 化学発癌 / Sorafenib

Outline of Final Research Achievements

The purpose of the study was to test if sorafenib can decrease the incidence of hepatocellular carcinoma (HCC) induced by diethyl nitrosoamine (DEN) with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH). Otsuka Long-Evans Tokushima Fatty (OLETF) was usued as a model of NAFLD/NASH. As a result, the incidence of HCC was decreased in sorafenib-treated groups irrespective of the presence of fatty liver. However, less number of animals survived after treatment of sorafenib as compared to sorafenib non-treated group. Although sorafenib can prevent occurrence of HCC, some of the NAFLD/NASH animals could not survive sorafenib related side effects probably due to their susceptibility to infection.